Equity Overview
Price & Market Data
Price: $4.41
Daily Change: $0.00 / 0.00%
Daily Range: $4.01 - $4.61
Market Cap: $1,532,903,936
Daily Volume: 4,234,467
Performance Metrics
1 Week: -0.23%
1 Month: -6.96%
3 Months: -50.78%
6 Months: 19.19%
1 Year: 146.4%
YTD: -50.78%
Company Details
Employees: 298
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.